ClinicalTrials.gg
Not yet recruitingNCT07729332Updated Jul 27, 2026

Switching to Oral Weight Management Pharmacotherapy to Prevent Weight Regain After GLP-1 Therapy Discontinuation

A Phase 4 interventional study of Phentermine Pill and Orforglipron in Obesity, sponsored by Massachusetts General Hospital. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-07-27.

Sponsored by Massachusetts General Hospital · Phase 4, Interventional, and Treatment

How we know · 3 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 22 studies testing orforglipron in Obesity — 4 open to participants now, 10 under way, 9 of them phase 3. orforglipron · Obesity.

Planned enrollment
19th of 22
60 · median 324
Started
2026
with 1 other
Phase 4
Only one
of the 22
Registered
21st of 22
by date
Lead sponsor
1 of 22
Massachusetts General Hospital

Among the 22 studies testing orforglipron in Obesity, this one is the 19th largest by planned enrollment, is one of 2 that started in 2026, is the only one in phase 4, and was the 21st registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

4 of the 22 studies testing orforglipron in Obesity are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About orforglipron

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing orforglipron in Obesity, or all of them as a file.
02

Study summary

This study will compare the effect of orforglipron and phentermine on weight maintenance.

03

Conditions studied

  • Obesity

Browse trials for

Keywords

  • weight maintenance
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18-80 years at screening
  2. History of ≥30 kg/m²
  3. Current or recent (within 8 weeks) treatment with injectable semaglutide, tirzepatide, or similar GLP-1 based medication
  4. Achieved ≥10% body weight loss since initiation of injectable semaglutide, tirzepatide or similar GLP-1 based medication
  5. Willing to participate in the study after reviewing study infographic and confirming understanding of randomization and study procedures
  6. Ability to understand and the willingness to sign a written document
  7. Residence in Massachusetts

Exclusion criteria

Exclusion Criteria:

  1. Current type 2 diabetes mellitus
  2. Recent or planned surgical obesity treatment (bariatric surgery >1 year prior to GLP-1 initiation allowed)
  3. Pregnancy, intent to become pregnant, or current breastfeeding (participants of must have a negative pregnancy test at baseline)
  4. History of pancreatitis
  5. History of transplanted organ (corneal transplants permitted) or awaiting organ transplant
  6. Obesity induced by endocrinologic disorders (e.g., Cushing syndrome) or diagnosed monogenic/syndromic obesity (e.g., MC4R deficiency, Prader-Willi syndrome)
  7. History of significant active or unstable major depressive disorder or other severe psychiatric disorder (e.g., schizophrenia, bipolar disorder, serious mood or anxiety disorder) within the past 2 years
  8. Any history of a suicide attempt
  9. Systemic therapy >2 weeks within the prior 3 months, or anticipated need within the next 12 months
  10. Use of medications known to cause significant weight gain (e.g., olanzapine, lithium) within the last 3 months.
  11. Quit using nicotine-containing products less than 6 months prior to baseline visit or intention to quit use in the next year
  12. Current use strong inducer medications (which may include: phenytoin, carbamazepine, phenobarbital, primidone, lumacaftor, midostaurin, and pentobarbital).
  13. Use of prescription or over-the-counter weight loss medications within the last 3 months, other than semaglutide, tirzepatide, or other injectable GLP-1 medication
  14. Chronic kidney disease stage 3b or lower ( \<45 mL/min/1.73m²)
  15. Acute hepatitis or liver failure/cirrhosis
  16. Known to phentermine:

    1. History of coronary artery, cerebrovascular or peripheral arterial disease including myocardial infarction, unstable angina, revascularization, stroke/, carotid intervention, claudication
    2. Poorly-controlled blood pressure (>149/94) or elevated heart rate (>110 bpm)
    3. History of cardiac arrhythmia
    4. History of valvular heart disease
    5. Congestive heart failure (any history or current)
    6. Active / currently-treated hyperthyroidism (thyroid function screening required if pulse>100)
    7. History of glaucoma or been told by an ophthalmologist that you are at high risk for glaucoma
    8. Heavy alcohol use within the last 6 months (men: more than 4 drinks on any day or more than 14 drinks per week; women: more than 3 drinks on any day or more than 7 drinks per week)
    9. History of substance use disorder or active use of illicit substances within the last 12 months. Tetrahydrocannabinol (THC)-containing products will not be considered an illicit substance. (e.g., uncontrolled hypertension, active/unstable cardiovascular disease, arrhythmia, hyperthyroidism [thyroid function screening required if pulse>100], glaucoma, history of substance use disorder

16. Use of any stimulant medications. 17. Known contraindication to orforglipron (e.g., personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2).

18. Any condition (e.g., drug or alcohol abuse, diagnosed eating disorder, other psychiatric disorder) that in the investigator's opinion may preclude protocol compliance

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Active comparator
    Phentermine

    Phentermine

    Drug: Phentermine Pill

  • Active comparator
    Orforglipron

    Orforglipron

    Drug: Orforglipron

Interventions

  • DrugPhentermine Pill

    Phentermine 8 mg or 37.5 mg tablet

  • orforglipron 0.8, 2.5, 5.5, 9, 14.5 or 17.2 mg tablets

06

What researchers measure

Primary outcomes

  1. Percent change in body weight

    Percent change in body weight from randomization to 6 months

    Time frame: 6 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided — It will be shared; data sharing plan is under review; will update when approved.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Jul 2031, 56 months later.

Of 190 non-industry phase 4 interventional studies under Obesity, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 52. This study's planned 56 months is above that.

Counting every sponsor, half of 210 studies reached it within 31 months; a quarter within 15 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 22, 2026
First posted
Jul 27, 2026
StartEst.
Nov 1, 2026
Primary completionEst.
Jul 31, 2031
CompletionEst.
Jul 31, 2031
Last update
Jul 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07729332
Responsible party
Deborah Wexler, MD (Associate Professor of Medicine, Harvard Medical School, Massachusetts General Hospital) — Principal investigator
First posted
Jul 27, 2026
Start date
Nov 1, 2026 (estimated)
Primary completion
Jul 31, 2031 (estimated)
Completion
Jul 31, 2031 (estimated)
Last update
Jul 27, 2026

Study contacts

Deborah J Wexler, MD
Contact
dwexler@mgh.harvard.edu
617-726-8767
Sarah Kanbour, MD
Contact
skanbour@mgh.harvard.edu
617-726-8767

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Orforglipron

Start the discussion